Despite significant advances in surgery, chemotherapy, radiotherapy, endocrine therapy,
and molecular-targeted therapy, breast cancer remains the leading cause of death from …

The immune system is designed to discriminate between self and tumor tissue. Through
genetic recombination, there is fundamentally no limit to the number of tumor antigens that …

Multi-agent chemotherapy is the standard treatment for most B cell malignancies. Since
chemotherapy can be associated with significant toxicity and since relapses resistant to …

In the final issue of Science in 2013, the American Association of Science recognized
progress in the field of cancer immunotherapy as the 'Breakthrough of the Year.'The …

Background It is urgent to explore an effective potential therapeutic strategy for ESCC. In
recent years, cell-based cancer immunotherapy has become a potentially close for …

Simple Summary Compared to the resounding success demonstrated in the field of B-cell
leukemia, lymphoma, and multiple myeloma, in the field of acute myeloid leukemia, CAR-T …

Neuroblastoma (NB), accounting for 10% of childhood cancers, exhibits aberrant cell-
surface glycosylation patterns. There is evidence that changes in glycolipids and protein …

Adoptive cell therapy (ACT) for cancer represents a promising new treatment modality. ACT
based on the administration of cytotoxic T cells genetically engineered to express a chimeric …

CAR (Chimeric Antigen receptor)-T cell therapy is a novel type of therapy that uses
engineered T cells with an antibody single-chain variable fragment (ScFv) extracellular …

Background and Objectives Anti-CD20 monoclonal antibody (mAb) B-cell depletion is a
remarkably successful multiple sclerosis (MS) treatment. Chimeric antigen receptor (CAR)-T …